- Source BioScience launches intelligent GenomeCUBE search engine
1 Sep 2014
Search and buying tool offers instant, simple access to millions of clone, antibody and protein products
Source BioScience, the international laboratory services and products business, today announced the launch of an updated version of its GenomeCUBE® search engine, an intelligent and powerful clone, antibody and protein products search and buying tool, which gives researchers easy access to millions of products, as well as Source BioScience’s scientific and technical support services.
Users can enter free text in GenomeCUBE (www.lifesciences.sourcebioscience.com/genomecube), which interrogates public databases as well as Source BioScience’s own stores of clone libraries and individual clone sets, associated antibodies and kits. The tool also automatically provides a separate list, based on the results, for appropriate antibodies, reagents and kits that you would expect the user to need. Searches can be based on clone identity, accession or other pertinent search terms such as gene symbols or gene and protein names. The system now also includes protein databases, to identify gene related antibodies, reagents and kits all in one place.
The search engine enables researchers to access reference content on each of the products, including ‘real-time’ annotated information from multiple public databases. Users can purchase all products they require directly through GenomeCUBE, eliminating the need to search the internet for various providers.
Dr Nick Ash, CEO of Source BioScience, commented: “We have made a significant investment in developing the new infrastructure and search capabilities of GenomeCUBE. The tool now offers users an easier pathway from search to checkout and payment. Using GenomeCUBE researchers can access the information they need, the associated products they may require and proceed to purchase this in as few as three clicks. We believe the market needs a search engine of this type, to enable researchers to access millions of clones, hundreds of thousands of antibodies and the ability to purchase the reagents and kits from one source.”